<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7256352\results\search\disease\results.xml">
  <result pre="Sciences, Ajman UniversityUnited Arab Emirates[f], Department of Nanotechnology, Faculty of" exact="Advanced" post="Sciences and Technology, Tehran Medical Sciences, Islamic Azad UniversityIran[g],"/>
  <result pre="of Molecular Sciences, Macquarie UniversityAustralia[h], Department of Microbiology, Faculty of" exact="Advanced" post="Sciences and Technology, Tehran Medical Sciences, Islamic Azad UniversityIran"/>
  <result pre="and Europe PMC, consistent with existing copyright protections.TBSD_A_1767210.pdf Abstract Abstract" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative"/>
  <result pre="Europe PMC, consistent with existing copyright protections.TBSD_A_1767210.pdf Abstract Abstract Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative representative"/>
  <result pre="PMC, consistent with existing copyright protections.TBSD_A_1767210.pdf Abstract Abstract Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is the causative representative of"/>
  <result pre="consistent with existing copyright protections.TBSD_A_1767210.pdf Abstract Abstract Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is the causative representative of a"/>
  <result pre="coronavirus 2 (SARS-CoV-2) is the causative representative of a severe" exact="respiratory" post="illness resulted in widespread human infections and deaths in"/>
  <result pre="representative of a severe respiratory illness resulted in widespread human" exact="infections" post="and deaths in nearly all of the countries since"/>
  <result pre="Remdesivir (RVD) as a potential anti-viral compound against Middle East" exact="respiratory" post="syndrome (MERS) -CoV, SARS-CoV and SARS-CoV-2. First, we overview"/>
  <result pre="(RVD) as a potential anti-viral compound against Middle East respiratory" exact="syndrome" post="(MERS) -CoV, SARS-CoV and SARS-CoV-2. First, we overview the"/>
  <result pre="alone or in combination with other anti-viral agents against CoVs" exact="infection" post="were surveyed to determine the efficiency of RDV in"/>
  <result pre="table-count: page-count: word-count: Introduction The new coronavirus (CoV), known as" exact="Severe" post="Acute Respiratory Syndrome (SARS)-CoV-2, which is currently spreading around"/>
  <result pre="page-count: word-count: Introduction The new coronavirus (CoV), known as Severe" exact="Acute" post="Respiratory Syndrome (SARS)-CoV-2, which is currently spreading around the"/>
  <result pre="word-count: Introduction The new coronavirus (CoV), known as Severe Acute" exact="Respiratory" post="Syndrome (SARS)-CoV-2, which is currently spreading around the world,"/>
  <result pre="Introduction The new coronavirus (CoV), known as Severe Acute Respiratory" exact="Syndrome" post="(SARS)-CoV-2, which is currently spreading around the world, can"/>
  <result pre="is currently spreading around the world, can lead to a" exact="respiratory" post="illness that can be exacerbated (Liu etÂ al., 2020;"/>
  <result pre="etÂ al., 2020; Novel, 2020; Xu etÂ al., 2020). The" exact="disease" post="known as CoV diseases-19 (COVID-19) appears to induce a"/>
  <result pre="2020). Two recent outbreaks of the new CoV, including severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)"/>
  <result pre="Two recent outbreaks of the new CoV, including severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS) have"/>
  <result pre="recent outbreaks of the new CoV, including severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS) have originated"/>
  <result pre="CoV, including severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS) have originated from animals (Gretebeck &amp;amp; Subbarao,"/>
  <result pre="including severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS) have originated from animals (Gretebeck &amp;amp; Subbarao, 2015;"/>
  <result pre="time intensive (Plotkin etÂ al., 2017). This includes finding a" exact="viral" post="sequence that, while providing memory to the immune system,"/>
  <result pre="memory to the immune system, does not lead to an" exact="acute" post="inflammatory reaction. Achieving this goal requires laboratory experimentation on"/>
  <result pre="more profitable to invest in drugs that are used for" exact="chronic" post="medical conditions. The CoV, as in case of influenza,"/>
  <result pre="could serve as potential candidates for the treatment of the" exact="viral" post="diseases (Andersen etÂ al., 2020; Ianevski etÂ al., 2018)."/>
  <result pre="approved anti-viral drugs could be a solution to treat new" exact="viral" post="infections (Guo, 2020; Kouznetsova etÂ al., 2014; Mercorelli etÂ"/>
  <result pre="anti-viral drugs could be a solution to treat new viral" exact="infections" post="(Guo, 2020; Kouznetsova etÂ al., 2014; Mercorelli etÂ al.,"/>
  <result pre="al., 2020). BSAAs are small molecules that can inhibit different" exact="infections" post="by blocking the viral replication (Pant etÂ al., 2020;"/>
  <result pre="small molecules that can inhibit different infections by blocking the" exact="viral" post="replication (Pant etÂ al., 2020; Xiong etÂ al., 2020;"/>
  <result pre="to an extent that the immune system can inhibit their" exact="infection" post="(Cui etÂ al., 2020; Ji &amp;amp; Li, 2020). BSAA"/>
  <result pre="has received special attention with the emergence of numerous new" exact="viral" post="diseases. Re-purposing existing drugs, or even rejected drugs, for"/>
  <result pre="viral diseases. Re-purposing existing drugs, or even rejected drugs, for" exact="viral" post="diseases increases the possibility of market success as well"/>
  <result pre="inÂ vitro studies have suggested that they can inhibit the" exact="viral" post="replication (Wang etÂ al., 2020). Teicoplanin, oritavancin, dalbavancin, and"/>
  <result pre="al., 2020). Teicoplanin, oritavancin, dalbavancin, and monensin antibiotics also prevent" exact="viral" post="replication (Andersen etÂ al., 2020). Currently, the BSAAs are"/>
  <result pre="reaches the clinical phase against MERS -CoV, SARS-CoV and SARS-CoV-2." exact="General" post="information on SARS-CoV-2 CoVs are a large family of"/>
  <result pre="Iran (Velavan &amp;amp; Meyer, 2020; Zhu etÂ al., 2020). The" exact="disease" post="can be spread through close contact with the infected"/>
  <result pre="outbreaks (Velavan &amp;amp; Meyer, 2020). Most people with hypertension, diabetes," exact="respiratory" post="problems, and weak immune systems are at the higher"/>
  <result pre="and weak immune systems are at the higher risk to" exact="infection" post="and the likely death from it (Fang etÂ al.,"/>
  <result pre="al., 2010). SARS-CoV-2 has proteins on its surface that mediate" exact="viral infection" post="by binding to angiotensin-converting enzyme 2 (ACE2) receptor (Batlle"/>
  <result pre="2010). SARS-CoV-2 has proteins on its surface that mediate viral" exact="infection" post="by binding to angiotensin-converting enzyme 2 (ACE2) receptor (Batlle"/>
  <result pre="Chen &amp;amp; Hao, 2020). Therefore, one promising way to stop" exact="infection" post="by SARS-CoV-2 is to find a compound that blocks"/>
  <result pre="a compound that blocks the receptor, and consequently prevent the" exact="infection" post="by preventing the interaction of S protein with ACE2"/>
  <result pre="by ORF1a/1b which act as important co-factors for activation of" exact="viral" post="replication enzymes (Guo etÂ al., 2020) (Figure 1). Figure"/>
  <result pre="of RDVâ€™s anti-viral function is based on the blockage of" exact="viral" post="RNA transcription as revealed in molecular examinations using different"/>
  <result pre="RNA transcription as revealed in molecular examinations using different recombinant" exact="viral" post="polymerases (Jordan etÂ al., 2018; Sarma etÂ al., 2020;"/>
  <result pre="reported that CoV is susceptible to the RDV targeting the" exact="viral" post="polymerase and the nsp14 exoribonuclease (ExoN). They compared the"/>
  <result pre="RDV, which ExoN (-) virus showed a greater decrease in" exact="viral" post="titer in the presence of GS-5734 relative to WT"/>
  <result pre="by GS-5734 (Figure 2A(ii)) indicated that GS-5734 is integrated into" exact="viral" post="genome and can be excluded by ExoN (Agostini etÂ"/>
  <result pre="time can play an important role on the inhibition of" exact="virus infection" post="(Figure 2B(iâ€&quot;iii). Figure 2. (A) ExoN (-) virus are"/>
  <result pre="can play an important role on the inhibition of virus" exact="infection" post="(Figure 2B(iâ€&quot;iii). Figure 2. (A) ExoN (-) virus are"/>
  <result pre="ExoN (-) virus are more sensitive to anti-viral drug. (i)" exact="Viral" post="titer of WT and ExoN (-) viruses, (ii) percentage"/>
  <result pre="titer of WT and ExoN (-) viruses, (ii) percentage of" exact="viral" post="titer reduction. (B) The effect of different variations on"/>
  <result pre="titer reduction. (B) The effect of different variations on the" exact="viral" post="titer value. (i) The SARS-CoV titer against different concentrations"/>
  <result pre="(Huh7) cells incubated with different agents, (ii) A decrease in" exact="viral" post="foci assayed by antibody staining, (iii) percentage of inhibition,"/>
  <result pre="2019). Lo etÂ al. (2019) also displayed that RDV prevent" exact="Nipah virus infection" post="in monkeys. Furthermore, to assess the reduction of MERS-CoV"/>
  <result pre="Lo etÂ al. (2019) also displayed that RDV prevent Nipah" exact="virus infection" post="in monkeys. Furthermore, to assess the reduction of MERS-CoV"/>
  <result pre="etÂ al. (2019) also displayed that RDV prevent Nipah virus" exact="infection" post="in monkeys. Furthermore, to assess the reduction of MERS-CoV"/>
  <result pre="infection in monkeys. Furthermore, to assess the reduction of MERS-CoV" exact="infection" post="inÂ vivo, Sheahan etÂ al. (2020) demonstrated that RDV"/>
  <result pre="that RDV was the only therapeutic agent which remarkably decreased" exact="pulmonary" post="infection. Figure 4. Percentage of inhibition of MERS-CoV replication"/>
  <result pre="by RDV, similar outcomes were observed for MERS-CoV along with" exact="limited" post="weight loss, increased pulmonary activity and decreased virus replication"/>
  <result pre="were observed for MERS-CoV along with limited weight loss, increased" exact="pulmonary" post="activity and decreased virus replication (Sheahan etÂ al., 2017)."/>
  <result pre="tissue reaches the maximum at 7â€&quot;10â€‰days after the onset of" exact="infections" post="and the disease severity increases to death within âˆ¼21â€‰days"/>
  <result pre="maximum at 7â€&quot;10â€‰days after the onset of infections and the" exact="disease" post="severity increases to death within âˆ¼21â€‰days (Choi etÂ al.,"/>
  <result pre="to a reduction in MERS-CoV pathogenesis and pronounced decrease in" exact="viral" post="dose, therapeutic handling did not thoroughly reduce infection. Furthermore,"/>
  <result pre="at high levels of CoV, RDV is unable to sustain" exact="viral" post="viability and pulmonary cells functionality, despite of remarkable decrease"/>
  <result pre="of CoV, RDV is unable to sustain viral viability and" exact="pulmonary" post="cells functionality, despite of remarkable decrease in viral loads."/>
  <result pre="viability and pulmonary cells functionality, despite of remarkable decrease in" exact="viral" post="loads. These outcomes are the same as those reported"/>
  <result pre="resultant outcomes (Sheahan etÂ al., 2017). Since SARS- and MERS-CoV" exact="infections" post="are controlled by both CoVs and host immune system"/>
  <result pre="proliferation and immunopathology, switch on repairing systems, or control the" exact="pulmonary" post="homeostasis. Current challenges and future opportunities Arising viral disorders"/>
  <result pre="control the pulmonary homeostasis. Current challenges and future opportunities Arising" exact="viral" post="disorders have resulted in meaningful catastrophic pandemics. Genetic exploration"/>
  <result pre="exploration in animal models have shown a pronounced mutation of" exact="viral" post="genome in the case of CoV, and have even"/>
  <result pre="etÂ al., 2013; Woo etÂ al., 2006). Therefore, in the" exact="absence of" post="FDA-approved therapeutics for reducing the human CoV infection, useful"/>
  <result pre="well as immunomodulators, either solely or combined, to reduce severe" exact="disease" post="symptoms (Zumla etÂ al., 2016). However, due to the"/>
  <result pre="dose combination of lopinavir/ritonavir-interferon Î² is efficient to reduce MERS-CoV" exact="infections" post="(Arabi etÂ al., 2018; Muralidharan etÂ al., 2020). Sheahan"/>
  <result pre="model progression of RDV seems to orient primarily on CoV" exact="respiratory" post="infections (Sheahan etÂ al., 2020). Clinical trials in selective"/>
  <result pre="progression of RDV seems to orient primarily on CoV respiratory" exact="infections" post="(Sheahan etÂ al., 2020). Clinical trials in selective patient"/>
  <result pre="Conclusion and perspective Due to the emergence of a new" exact="respiratory" post="infections such as the SARS-CoV-2, progression of animal studies"/>
  <result pre="and perspective Due to the emergence of a new respiratory" exact="infections" post="such as the SARS-CoV-2, progression of animal studies and"/>
  <result pre="for additional trials of RDV against a wider range of" exact="infectious" post="including COVID-19. The ongoing studies in SARS-CoV-2 supported by"/>
  <result pre="RDV for treating SARS- and MERS-CoVs, the emergence of other" exact="viral" post="illnesses may pave the way for clinical trials of"/>
  <result pre="L., ClarkeM. O., BaricR. S., &amp;amp; DenisonM. R. (2018). Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonuclease. MBio, 9(2), 21810.1128/mBio.00221-18 AhmedS."/>
  <result pre="and development of safe-in-man broad-spectrum antiviral agents. International Journal of" exact="Infectious" post="Diseases: IJID: Official Publication of the International Society for"/>
  <result pre="Infectious Diseases: IJID: Official Publication of the International Society for" exact="Infectious" post="Diseases, 93, 268â€&quot;276. 10.1016/j.ijid.2020.02.01832081774 ArabiY. M., AlothmanA., BalkhyH. H.,"/>
  <result pre="A., QushmaqI., &amp;amp; HusseinM. A. (2018). Treatment of Middle East" exact="Respiratory" post="Syndrome with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE"/>
  <result pre="QushmaqI., &amp;amp; HusseinM. A. (2018). Treatment of Middle East Respiratory" exact="Syndrome" post="with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE trial):"/>
  <result pre="(2020). Soluble angiotensin-converting enzyme 2: A potential approach for coronavirus" exact="infection" post="therapy?Clinical Science, 134(5), 543â€&quot;545. 10.1042/CS2020016332167153 BoopathiS., PomaA. B., &amp;amp;"/>
  <result pre="role of angiotensin converting enzyme 2 in coronaviruses/influenza viruses and" exact="cardiovascular disease." post="Cardiovascular Research. 10.2139/ssrn.3537961 ChenW.-H., StrychU., HotezP. J., &amp;amp; BottazziM."/>
  <result pre="ChhikaraB. S., RathiB., SinghJ., &amp;amp; PoonamF. (2020). Corona virus SARS-CoV-2" exact="disease" post="COVID-19: Infection, prevention and clinical advances of the prospective"/>
  <result pre="&amp;amp; KimY.-S. (2016). Clinical presentation and outcomes of Middle East" exact="respiratory" post="syndrome in the Republic of Korea. Infection &amp;amp; Chemotherapy,"/>
  <result pre="KimY.-S. (2016). Clinical presentation and outcomes of Middle East respiratory" exact="syndrome" post="in the Republic of Korea. Infection &amp;amp; Chemotherapy, 48(2),"/>
  <result pre="of Middle East respiratory syndrome in the Republic of Korea." exact="Infection" post="&amp;amp; Chemotherapy, 48(2), 118â€&quot;126. 10.3947/ic.2016.48.2.11827433382 CuiH., ZhangC., ZhaoZ., ZhangC.,"/>
  <result pre="web-based dashboard to track COVID-19 in real time. The Lancet" exact="Infectious" post="Diseases, 20(5), 533â€&quot;534. 10.1016/S1473-3099(20)30120-132087114 DouglasM. G., KocherJ. F., ScobeyT.,"/>
  <result pre="BaricR. S., &amp;amp; CockrellA. S. (2018). Adaptive evolution influences the" exact="infectious" post="dose of MERS-CoV necessary to achieve severe respiratory disease."/>
  <result pre="influences the infectious dose of MERS-CoV necessary to achieve severe" exact="respiratory" post="disease. Virology, 517, 98â€&quot;107. 10.1016/j.virol.2017.12.00629277291 ElmezayenA. D., Al-ObaidiA., ÅžahinA."/>
  <result pre="1â€&quot;19. 10.1080/07391102.2020.1756411 FangL., KarakiulakisG., &amp;amp; RothM. (2020). Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?The"/>
  <result pre="FangL., KarakiulakisG., &amp;amp; RothM. (2020). Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?The Lancet Respiratory Medicine,"/>
  <result pre="and diabetes mellitus at increased risk for COVID-19 infection?The Lancet" exact="Respiratory" post="Medicine, 8(4), e2110.1016/S2213-2600(20)30116-832171062 FungS.-Y., YuenK.-S., YeZ.-W., ChanC.-P., &amp;amp; JinD.-Y."/>
  <result pre="YuenK.-S., YeZ.-W., ChanC.-P., &amp;amp; JinD.-Y. (2020). A tug-of-war between severe" exact="acute" post="respiratory syndrome coronavirus 2 and host antiviral defence: Lessons"/>
  <result pre="YeZ.-W., ChanC.-P., &amp;amp; JinD.-Y. (2020). A tug-of-war between severe acute" exact="respiratory" post="syndrome coronavirus 2 and host antiviral defence: Lessons from"/>
  <result pre="ChanC.-P., &amp;amp; JinD.-Y. (2020). A tug-of-war between severe acute respiratory" exact="syndrome" post="coronavirus 2 and host antiviral defence: Lessons from other"/>
  <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus. The Journal of Biological Chemistry, 295(15), 4773â€&quot;4779."/>
  <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus. The Journal of Biological Chemistry, 295(15), 4773â€&quot;4779. 10.1074/jbc.AC120.01305632094225"/>
  <result pre="for new enemy: Drug repurposing for treatment of newly emerging" exact="viral" post="diseases. Virologica Sinica, 1â€&quot;3. 10.1007/s12250-020-00204-731916022 GuoY.-R., CaoQ.-D., HongZ.-S., TanY.-Y.,"/>
  <result pre="YanY. (2020). The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreakâ€&quot;an update on the status. Military Medical"/>
  <result pre="(2020). In-silico approaches to detect inhibitors of the human severe" exact="acute" post="respiratory syndrome coronavirus envelope protein ion channel. Journal of"/>
  <result pre="In-silico approaches to detect inhibitors of the human severe acute" exact="respiratory" post="syndrome coronavirus envelope protein ion channel. Journal of Biomolecular"/>
  <result pre="approaches to detect inhibitors of the human severe acute respiratory" exact="syndrome" post="coronavirus envelope protein ion channel. Journal of Biomolecular Structure"/>
  <result pre="Infections,3(1), 1â€&quot;7. 10.1038/emi.2014.88 LaiC.-C., ShihT.-P., KoW.-C., TangH.-J., &amp;amp; HsuehP.-R. (2020)." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus"/>
  <result pre="1â€&quot;7. 10.1038/emi.2014.88 LaiC.-C., ShihT.-P., KoW.-C., TangH.-J., &amp;amp; HsuehP.-R. (2020). Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019"/>
  <result pre="10.1038/emi.2014.88 LaiC.-C., ShihT.-P., KoW.-C., TangH.-J., &amp;amp; HsuehP.-R. (2020). Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19):"/>
  <result pre="LaiC.-C., ShihT.-P., KoW.-C., TangH.-J., &amp;amp; HsuehP.-R. (2020). Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the"/>
  <result pre="FeldmannH., SpiropoulouC. F., &amp;amp; de WitE. (2019). Remdesivir (GS-5734) protects" exact="African" post="green monkeys from Nipah virus challenge. Science Translational Medicine,"/>
  <result pre="11(494), eaau924210.1126/scitranslmed.aau924231142680 MackieP. (2003). The classification of viruses infecting the" exact="respiratory" post="tract. Paediatric Respiratory Reviews, 4(2), 84â€&quot;90. 10.1016/S1526-0542(03)00031-912758044 MahaseE. (2020)."/>
  <result pre="(2003). The classification of viruses infecting the respiratory tract. Paediatric" exact="Respiratory" post="Reviews, 4(2), 84â€&quot;90. 10.1016/S1526-0542(03)00031-912758044 MahaseE. (2020). Coronavirus: Covid-19 has"/>
  <result pre="has killed more people than SARS and MERS combined, despite" exact="lower" post="case fatality rate. British Medical Journal Publishing Group. MenÃ©ndez-AriasL.,"/>
  <result pre="Group. MenÃ©ndez-AriasL., Ã�lvarezM., &amp;amp; PachecoB. (2014). Nucleoside/nucleotide analog inhibitors of" exact="hepatitis" post="B virus polymerase: Mechanism of action and resistance. Current"/>
  <result pre="1â€&quot;9. 10.1016/j.coviro.2014.04.00524814823 MercorelliB., PalÃ¹G., &amp;amp; LoregianA. (2018). Drug repurposing for" exact="viral" post="infectious diseases: How far are we?Trends in Microbiology, 26(10),"/>
  <result pre="10.1016/j.coviro.2014.04.00524814823 MercorelliB., PalÃ¹G., &amp;amp; LoregianA. (2018). Drug repurposing for viral" exact="infectious" post="diseases: How far are we?Trends in Microbiology, 26(10), 865â€&quot;876."/>
  <result pre="(2018). Clinical outcomes of current medical approaches for Middle East" exact="respiratory" post="syndrome: A systematic review and metaâ€�analysis. Reviews in Medical"/>
  <result pre="KimE. S., KimH. B., ParkS. W., &amp;amp; KimN. J. (2016)." exact="Viral" post="load kinetics of MERS coronavirus infection. The New England"/>
  <result pre="L., &amp;amp; YangL. (2020). Time course of lung changes on" exact="chest" post="CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia."/>
  <result pre="&amp;amp; ByrareddyS. N. (2020). The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreak. Journal of Autoimmunity, 109, 10243310.1016/j.jaut.2020.10243332113704 SarmaP., SekharN.,"/>
  <result pre="epidemiological and clinical features of the emerging 2019 novel coronavirus" exact="pneumonia" post="(COVIDâ€�19) implicate special control measures. Journal of Medical Virology,"/>
  <result pre="Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS" exact="Infectious" post="Diseases, 6(5), 909â€&quot;915. 10.1021/acsinfecdis.0c0005232125140 XuM., LeeE. M., WenZ., ChengY.,"/>
  <result pre="HuangW., â€¦ TangH. (2016). Identification of small-molecule inhibitors of Zika" exact="virus infection" post="and induced neural cell death via a drug repurposing"/>
  <result pre="â€¦ TangH. (2016). Identification of small-molecule inhibitors of Zika virus" exact="infection" post="and induced neural cell death via a drug repurposing"/>
  <result pre="ZhaoJ., &amp;amp; WangF.-S. (2020). Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndrome. The Lancet Respiratory Medicine, 8(4), 420â€&quot;422."/>
  <result pre="&amp;amp; WangF.-S. (2020). Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome. The Lancet Respiratory Medicine, 8(4), 420â€&quot;422. 10.1016/S2213-2600(20)30076-X32085846"/>
  <result pre="of COVID-19 associated with acute respiratory distress syndrome. The Lancet" exact="Respiratory" post="Medicine, 8(4), 420â€&quot;422. 10.1016/S2213-2600(20)30076-X32085846 YaoY., BaoL., DengW., XuL., LiF.,"/>
  <result pre="&amp;amp; QinC. (2014). An animal model of MERS produced by" exact="infection" post="of rhesus macaques with MERS coronavirus. The Journal of"/>
  <result pre="infection of rhesus macaques with MERS coronavirus. The Journal of" exact="Infectious" post="Diseases, 209(2), 236â€&quot;242. 10.1093/infdis/jit59024218506 ZhuZ., ZhongC., ZhangK., DongC., PengH.,"/>
  <result pre="ZhongC., ZhangK., DongC., PengH., XuT., WangA., GuoZ., &amp;amp; ZhangY. (2020)." exact="Epidemic" post="trend of corona virus disease 2019 (COVID-19) in mainland"/>
  <result pre="WangA., GuoZ., &amp;amp; ZhangY. (2020). Epidemic trend of corona virus" exact="disease" post="2019 (COVID-19) in mainland China. Zhonghua yu Fang yi"/>
 </snippets>
</snippetsTree>
